INVESTIGATION



# Experimental Mutations in Superoxide Dismutase 1 Provide Insight into Potential Mechanisms Involved in Aberrant Aggregation in Familial Amyotrophic Lateral Sclerosis

Anthony M. Crown,<sup>\*,†,1</sup> Brittany L. Roberts,<sup>\*,†,1</sup> Keith Crosby,<sup>\*,1</sup> Hilda Brown,<sup>\*</sup> Jacob I. Ayers,<sup>\*</sup> P. John Hart,<sup>‡,§</sup> and David R. Borchelt<sup>\*,\*\*,2</sup>

\*Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, <sup>†</sup>College of Arts and Sciences, \*\*SantaFe HealthCare Alzheimer's Disease Research Center, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, <sup>‡</sup>Department of Veterans Affairs, South Texas Veterans Health Care System, San Antonio, TX 78229, and <sup>§</sup>Department of Biochemistry University of Texas Health Science Center, San Antonio, TX 78229 ORCID IDs: 0000-0003-3884-6223 (A.M.C.); 0000-0003-4544-2366 (J.I.A.)

**ABSTRACT** Mutations in more than 80 different positions in superoxide dismutase 1 (SOD1) have been associated with amyotrophic lateral sclerosis (fALS). There is substantial evidence that a common consequence of these mutations is to induce the protein to misfold and aggregate. How these mutations perturb native structure to heighten the propensity to misfold and aggregate is unclear. In the present study, we have mutagenized Glu residues at positions 40 and 133 that are involved in stabilizing the  $\beta$ -barrel structure of the native protein and a critical Zn binding domain, respectively, to examine how specific mutations may cause SOD1 misfolding and aggregation. Mutations associated with ALS as well as experimental mutations were introduced into these positions. We used an assay in which mutant SOD1 was fused to yellow fluorescent protein (SOD1:YFP) to visualize the formation of cytosolic inclusions by mutant SOD1. We then used existing structural data on SOD1, to predict how different mutations might alter local 3D conformation. Our findings reveal an association between mutant SOD1 aggregation and amino acid substitutions that are predicted to introduce steric strain, sometimes subtly, in the 3D conformation of the peptide backbone.

## **KEYWORDS**

mutagenesis structure protein aggregation cell models

Approximately 10–20% of ALS cases with a family history have mutations in Cu-Zn superoxide dismutase (SOD1) (Rosen *et al.* 1993). The native form of this ubiquitously expressed antioxidant enzyme is a homodimer of two 153 amino acid subunits (McCord and Fridovich

1969; Fridovich 1974). The native structure of the protein contains eight  $\beta$ -strands, a catalytic copper ion, a structurally important zinc ion, an electrostatic loop element that forms a portion of the active site funnel, and an intramolecular disulfide bond between cysteine 57 and cysteine 146 (Parge et al. 1992; Ogihara et al. 1996; Hart et al. 1999). The vast majority of the more than 160 SOD1 mutations associated with ALS are missense point mutations {http://alsod.iop.kcl.ac.uk}. Some of these point mutations have been shown to diminish normal enzyme activity or accelerate protein turnover; whereas other mutations have limited effects on activity or protein half-life (Gurney et al. 1994; Borchelt et al. 1994; Nishida et al. 1994; Wong et al. 1995; Wiedau-Pazos et al. 1996; Ratovitski et al. 1999; Hayward et al. 2002; Jonsson et al. 2004; Wang et al. 2005; Jonsson et al. 2006b). In autopsy studies of SOD1 ALS cases, SOD1 immuno-reactive inclusions in spinal cord are commonly, but not uniformly, found pathologic features (Shibata et al. 1996a, 1996b; Shaw et al. 1997; Sasaki et al. 1998; Kokubo et al. 1999; Kato et al. 2001; Takehisa et al. 2001; Tan et al.

Copyright © 2019 Crown *et al.* 

doi: https://doi.org/10.1534/g3.118.200787

Manuscript received October 9, 2018; accepted for publication January 1, 2019; published Early Online January 8, 2019.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/ licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplemental material available at Figshare: https://doi.org/10.25387/ g3.7474946.

 $<sup>{}^{\</sup>check{\mbox{\scriptsize I}}} These$  authors contributed equally to the content of this paper.

<sup>&</sup>lt;sup>2</sup>To whom correspondence should be addressed: Department of Neuroscience, Box 100159, 1275 Center Drive, University of Florida, Gainesville, FL 32610. E-mail: drb1@ufl.edu.

2004; Ohi *et al.* 2004; Jonsson *et al.* 2008; Suzuki *et al.* 2008; Kerman *et al.* 2010; Hineno *et al.* 2012; Sábado *et al.* 2013; Nakamura *et al.* 2014; Steinacker *et al.* 2014). Studies in a variety of model systems have reported that the ALS-associated mutations in SOD1 cause the protein to be more prone to misfold and aggregate (Johnston *et al.* 2000; Shinder *et al.* 2001; Wang *et al.* 2002; Elam *et al.* 2003; Jonsson *et al.* 2004; Prudencio *et al.* 2009). Misfolded SOD1 has also been described as a pathologic feature of sporadic ALS using antibodies that are preferentially reactive to non-natively folded SOD1 (Bosco *et al.* 2010; Forsberg *et al.* 2010; Grad *et al.* 2014). Other studies, however, have disputed these findings (Brotherton *et al.* 2012; Ayers *et al.* 2014b; Da Cruz *et al.* 2017).

The majority of studies in cell and mouse models have suggested that mutant SOD1 is generally more prone to misfold and aggregate, but the distinction is not absolute. In vitro, purified WT SOD1 can be readily induced to aggregate into amyloid-like fibrillary structures by de-metalation (Cu) and disulfide reduction (Rakhit et al. 2002; DiDonato et al. 2003; Furukawa and O'Halloran 2005; Chattopadhyay et al. 2008, 2015; Banci et al. 2008; Furukawa et al. 2010; Pratt et al. 2014; Abdolvahabi et al. 2015, 2016). Similarly, de-metalation and reduction of purified fALS mutant SOD1 also induces fibrillary amyloid structures (Münch and Bertolotti 2010; Vassall et al. 2011; Pratt et al. 2014; Abdolvahabi et al. 2016). In these in vitro assays, the differences in aggregation propensity between WT and fALS mutant SOD1 are variably evident (Banci et al. 2008; Furukawa et al. 2010). Some studies have reported that fALS mutants aggregate more rapidly in vitro (Münch and Bertolotti 2010; Vassall et al. 2011; Pratt et al. 2014), and are more prone to oligomerization (Furukawa and O'Halloran 2005; Münch and Bertolotti 2010; Vassall et al. 2011). However, a recent study that examined the rates of aggregation for a panel of ALS mutants in vitro, using Thioflavin T assays, reported that the assay exhibits considerable variability making it difficult to reliably say whether purified SOD1 with fALS mutations reproducibly aggregates faster (Abdolvahabi et al. 2016). Additionally, competition between the formation of amyloid-like structures that bind Thioflavin T, the reporter dye used for assessing SOD1 aggregation, and the formation of amorphous aggregates that do not bind the dye is a confounding factor in assessing SOD1 aggregation (Abdolvahabi et al. 2016). Interestingly, SOD1 aggregates generated in vitro in the presence of lipids tend to be more amorphous in structure (Choi et al. 2011). Purified Holo pseudo WT-SOD1 (pSOD1, fully metallated, presumably with a correct intramolecular disulfide bond, encoding mutations C6A, C111S) is slow to aggregate in vitro (days as compared to hours for demetalled SOD1) and generally forms non-amyloid aggregates (Hwang et al. 2010). The addition of fALS mutations, such as A4V, A4T, G85R, G93A, and I149T, to pseudo WT-SOD1 generally appears to decrease the lag phase for aggregate formation, but this effect is not consistent across all mutants; A4S, G93D, G93V, and G93S show little or no difference from Holo pSOD1 (Hwang et al. 2010). Collectively, these studies demonstrate that SOD1 could be viewed as inherently prone to aggregation, and illustrate some of the challenges in defining whether disease-associated mutations alter aggregation propensity in vitro.

In mouse models of WT and mutant SOD1 over-expression, mutant SOD1 appears to be significantly more prone to aggregate (Graffmo *et al.* 2013). Mice expressing high levels of human WT SOD1 develop ALS-like paresis but at much later ages than mice expressing equivalent levels of mutant SOD1. At end-stage, the levels of mis-folded, aggregated SOD1 in paralyzed mice expressing WT SOD1 were about half the level in paralyzed mice expressing the G93A mutant SOD1 (Graffmo *et al.* 2013). Mice expressing WT-SOD1 fused to yellow

fluorescent protein (SOD1:YFP) do not develop ALS-like paralysis and do not show evidence of WT-SOD1:YFP aggregation at advanced ages; whereas equivalently expressed fALS mutant G85R-SOD1:YFP produces paralysis with obvious inclusion pathology (Wang et al. 2009). Similar data for SOD1:YFP fusion proteins has been described in cultured cell models of over-expression (Corcoran et al. 2004; Matsumoto et al. 2005; Turner et al. 2005; Fei et al. 2006; Zhang and Zhu 2006; Urushitani et al. 2008; Witan et al. 2009). We have demonstrated that SOD1:YFP fusions with fALS mutations A4V, G37R, G85R, D101N, C111Y, S134N all readily form fluorescent inclusions when over-expressed in cultured cells (Prudencio and Borchelt 2011; Roberts et al. 2012). WT-SOD1:YFP displays a diffuse distribution in the cytoplasm and readily diffuses out of permeabilized cells whereas mutant SOD1 fused to YFP forms immobile inclusions (Prudencio and Borchelt 2011). Untagged versions of SOD1 with ALS mutations (>40 mutants tested) form detergent insoluble, sedimentable, aggregates when transiently over-expressed in cell models (Wang et al. 2003; Karch and Borchelt 2008; Prudencio et al. 2009). SOD1:YFP tagged variants of mutant SOD1 that form inclusions are similarly sedimentable and detergent-insoluble (Prudencio and Borchelt 2011). Collectively, this body of work demonstrates that fALS mutations in SOD1 share a common feature of promoting aggregation of the protein, and that visualizing aggregation by expressing YFP fusion proteins in cells models is a useful approach.

The objective of the current study was to investigate how amino acid substitutions may induce the aggregation of SOD1. As outlined above, there have been many studies of aggregation by SOD1 with fALS point mutations, but there has not been an assessment of how tolerant a given position might be for different types of substitutions. Here, we focus on two amino acid positions in SOD1 that are in critical structural locations in the protein, Glu 40 and Glu 133. Glu 40 is located in a loop domain that is juxtaposed to Lys 91 within a portion of the protein that forms an element called a  $\beta$ -barrel plug, which creates a barrier to exclude solvent from the hydrophobic core of SOD1's beta barrel structure (Figure 1)(Hart *et al.* 



**Figure 1** Image of homodimeric SOD1 structure. A representation of SOD1 homodimer structure (protein data bank 2v0a) captured from a 3-D representation created in LiteMol through the Protein Data Bank in Europe (https://www.ebi.ac.uk/pdbe/entry/pdb/2V0A). The locations of E40 and E133 are noted in one of the two subunits visible in the image.

1998, 1999). Glu 133 is located in an alpha helical segment in a loop element that is critical in binding Zn (Figure 1). These amino acids were mutated to encode either ALS mutations or specific experimental mutations within SOD1:YFP fusion constructs, and we then assessed aggregation of the protein. Our experimental data suggests that mutations that disrupt van der Wäals interactions or introduce steric strain are poorly tolerated and are associated with a higher propensity to aggregate.

## **MATERIALS AND METHODS**

#### Generation of mutant SOD plasmids

Mutations were introduced in human *SOD1* cDNA using oligonucleotide primers encoding the desired mutation with QuikChange mutagenesis kits (Agilent Technologies, Santa Clara, CA). The cDNA gene for *SOD1* was mutagenized in pEF.BOS vectors (Mizushima and Nagata 1990) that encode WT-SOD1:YFP cDNA (Prudencio and Borchelt 2011) as the template. The PCR reaction used Platinum *Pfx* polymerase (Invitrogen/ThermoFisher, Waltham, MA) and 2X Pfx buffer concentration to accommodate the large plasmids that were amplified. The PCR reaction products were digested with Dpn1 to remove template and then transformed into NEB-10 $\beta$  competent cells (New England Biolabs, Ipswich, MA) following standard protocols. Large scale preparations of plasmid DNA for transfection were prepared by CsCl gradient purification. The SOD1:YFP coding elements of all plasmids produced from CsCl purification was verified by DNA sequence analysis.

#### **Transient Transfections**

Expression plasmids were transiently transfected into Chinese hamster ovary (CHO) cells grown on 60-mm poly-D-lysine-coated dishes (1 plate for each DNA construct). Upon reaching 95% confluency, cells were transfected with Lipofectamine 2000 (Invitrogen/ThermoFisher). The cells were then incubated at 37° in a CO<sub>2</sub> incubator for 24 hr at which time images of random fields of view at 20x and 40 × magnification were captured using an AMG EVOS<sub>fl</sub> digital inverted microscope for fluorescence. The cells were returned to the incubator for 24 hr before images were captured again. The transient transfections were repeated at least 3 times for each construct. The images from multiple transfections were analyzed and cells showing YFP fluorescence and cells showing fluorescent inclusions were counted.

## Immunoblotting

At 48 hr post-transfection, CHO cells were washed from the plate in 1X PBS, and then centrifuged at 3000xg rpm for 5 min before resuspension in 1X PBS with protease inhibitor cocktail (Sigma, St. Louis, MO, USA). Cells were disrupted with a probe sonicator by three 10 sec bursts, and protein concentrations determined with BCA assay (Pierce/ThermoFisher, Waltham, MA). From these lysates,  $5\mu$ g of protein was separated by electrophoresis in 18% TG-SDS PAGE gels (Invitrogen/ThermoFisher). After transfer to nitrocellulose membrane, the SOD1:YFP proteins were revealed by incubation with SOD1 rabbit polyclonal antibody (Ratovitski *et al.* 1999) and detection by enhanced chemiluminesence as previously described (Ayers *et al.* 2014a).

## **Molecular Modeling**

The observed conformations (rotamers) adopted by the side chains of residues E40, K91 and E133 were visualized by superimposing all of the wild type SOD1 subunits available in the protein data bank (PDB). The possible structural consequences of amino acid substitutions at positions

E40 and E133 were examined *in silico* using the structure of wild type human SOD1 refined to 1.15 Å as the template [pdb code 2v0a (Strange *et al.* 2007)]. Substitutions for E40 and E133 were introduced into the human wild type template structure and all possible backbone dependent and independent rotamers for the substituted residues were scrutinized using the mutagenesis wizard in program PyMol (The PyMol Molecular Graphics System, Version 1.7.0, Schrödinger, LLC).

## **Data and Reagent Availability**

All recombinant DNA constructs used in this study are available upon request. The authors confirm that all data necessary for confirming the conclusions of the article are present within the article, figures, tables, and supplemental materials. Supplemental material available at Figshare: https://doi.org/10.25387/g3.7474946.

## **RESULTS AND DISCUSSION**

In prior studies, we have used both HEK293 and Chinese Hamster Ovary (CHO) cells to visualize the aggregation of mutant SOD1 fused to YFP,



**Figure 2** Example of the images that were scored to assess the frequency of inclusion formation by variants SOD1 encoding amino acid substitutions at residue E40. Recombinant DNA vectors encoding SOD1 fused in-frame to YFP were transfected into CHO cells as described in Methods and images were captured at 24 and 48 hr. The E40G mutation has been associated with ALS, whereas the E40V, E40Q, and E40D mutations are experimental substitutions.

finding similar results (Prudencio and Borchelt 2011; Roberts et al. 2012). In the present study, we used the CHO cell model because these cells have a large cytosol compartment that allows for a clear assessment of inclusion formation by the fusion proteins. Prior studies have established that the formation of inclusions by these fusion proteins in cell models correlates to changes in protein solubility and mobility (Prudencio and Borchelt 2011). Within the time frame of these 48 hr transfections, CHO cells do not show significant cell death due to mutant SOD1 expression (Prudencio and Borchelt 2011). Additionally, in this CHO model of transient transfection, the SOD1:YFP proteins are highly over-expressed in a subset of cells, overwhelming any modulation of aggregation by chaperone function that could occur and minimizing variabilities in protein half-life (Prudencio et al. 2009; Ayers et al. 2014a). In previous studies of SOD1 in these overexpression cell models, we have determined that both WT and mutant SOD1 are largely deficient in Cu ions and that mutant SOD1 is substantially less able to form the normal intramolecular disulfide bond associated with full maturation (Avers et al. 2014a). Thus, the model assesses the inherent propensity of immature mutant SOD1 to aggregate. The use of the visual assay helps to control for variations in expression levels as fluorescence intensity can be used as a gauge for relative expression. As described in Methods, three transient transfections were performed for each construct and representative images were captured at 24 and 48 hr. For quantitative analysis of aggregate formation, cells expressing the fusion proteins were identified by fluorescence and scored for the presence of inclusion-like structures. Examples of what the observer scored are shown in Figure 2. Cells were scored as having inclusions when the observer could clearly discern the presence of multiple highly fluorescent puncta within the cytosol. A subset of cells in these images show changes in morphology in which they adopt a rounded appearance due to detachment from the culture surface. The rounded cells were generally not counted because they were slightly out of focus relative to the flatter cells.

The E40 and E133 positions that encode Glu were first mutated to amino acid substitutions that are known to be associated with ALS. Mutation of E40 to G is listed in the ALSOD database {http://alsod.iop. kcl.ac.uk} as a disease-causing mutation as are two different types of mutations at E133 (E133del, E133V), however, data on the number of ALS patients with these mutations is limited. The E40 position was also mutated experimentally to non-conservative Val or Gln residues, and a conservative Asp residue. As expected for mutations associated with fALS, the E40G variant produced inclusions at relatively high frequency (Figure 2; Table 1). Mutation of E40 to V also produced inclusions (Figure 3), but less frequently than the E40G-SOD1:YFP variant (Table 1). The E40Q SOD1:YFP construct did not form any obvious inclusions at 24 or 48 hr (Figure 2; Table 1; the image shown in Figure 2 has several examples of rounded out of focus cells which appear much brighter due to light diffraction). To discern the effect of conservative mutations at this site, we generated an E40D variant, finding that this variant produced inclusions at frequencies well above background at both 24 and 48 hr (Figure 2, Table 1).

To identify a potential molecular basis for our observations, we examined the available data on SOD1 3-D structure to identify features of these amino acid substitutions that could cause aggregation. To obtain an unbiased representation of the hSOD1 WT structure around E40, we examined 7 different WT structures from the protein data bank, including 32 protomers [same approach as described in (Ayers et al. 2014b)], and structurally aligned each protomer to generate a representative or "consensus" structure. K91 is positioned at the apex of the type I β-turn between strands 5 and 6, whereas E40 is located in the omega loop between  $\beta$ -strands 3 and 4. The type 1  $\beta$ -turn and omega loop are in contact, coming together to close one end of the  $\beta$ -barrel (Figure 3A & B). At the midpoint of the omega loop, L38 acts as an apolar "plug" of the β-barrel where it engages in multiple apolar interactions with residues coming from neighboring structural elements (e.g., V14, I35, F45, V87, A89, A95, V119, and L144, Figure 3A). Mutations associated with ALS have been found at all but two of these positions (35 and 119) {http://alsod.iop.kcl.ac.uk}. The side chain of K91 is observed in several conformations (Figure 3A). The  $\beta$ -hairpin and omega loop elements are highly complementary in shape and are associated primarily through van der Wäals contacts and several mainchain to main-chain hydrogen bonds (Figure 3B). The absence of side chains at G37, G41, and G93 (purple sphere, Figure 3B) is important for this shape complementarity. Mutations of G37 to R or V, G41 to S or D, and G93 to A, C, D, S, R, or V have been associated with ALS {http:// alsod.iop.kcl.ac.uk}. K91 donates a hydrogen bond to the side chain of D92 in five protomers, makes no hydrogen bond in 23 protomers (Figure 3B), and donates a hydrogen bond to the side chain of E40 in 8 protomers (Figure 3C). The side chain of E40 is essentially invariant in all structures, engaging in van der Wäals interaction with the backbone of the loop formed by residues 90-93 (Figure 3B & C). Mutation of E40 to G is predicted to weaken van der Wäals contacts and

SOD1 Variant	# cells counted (24 hr)	# cells w/ inclusions (24 hr)	% cells w/ inclusions (24 hr)	# cells counted (48 hr)	# cells w/ inclusions (48 hr)	% cells w/ inclusions (48 hr)	Predicted structural consequence
WT	656	5	≤ 1%	742	6	1%	N/A
G93A*	333	78	23%	503	243	48%	Steric clash
E40D	187	64	34%	267	61	23%	Loss of van der Wäals, Steric clash
E40G*	267	78	29%	238	186	78%	Loss of van der Wäals
E40Q	217	0	0%	229	0	0%	None
E40V	116	28	24%	147	37	25%	Steric clash
E133D	219	0	0%	197	0	0%	None
E133G	221	0	0%	288	0	0%	None
E133L	275	0	0%	373	0	0%	None
E133M	243	0	0%	265	0	0%	None
E133V*	324	38	12%	254	62	24%	Steric clash
E133Del*	192	12	6%	255	60	24%	Loss of H-bonds

Table 1 Summary of inclusion formation by mutant SOD1 constructs examined with predicted structural consequence caused by each mutation

\*sequence variants associated with ALS.



Figure 3 Local structure near β-barrel plug (L38) in WT SOD1 and predicted impact of E40 substitutions. A, Superposition of 36 unique protomers of WT hSOD1 available in the Protein Data Bank [see Table S2 in (Ayers et al. 2014b) ] reveals an ensemble of conformers of the side chains of E40, D90, K91, and D92. The color-coding of consecutive betastrands includes residues in connecting loops. Strands 1-2 (blue), strands 3-4 (cyan), strands 5-6 (yellow), strands 7-8 (orange), electrostatic loop (loop VII, red). B and C, The packing of the 3-4 loop with the 5-6 loop maximizes van der Wäals contacts. The extended side chain of E40 makes favorable contacts with atoms of K91, sealing the apolar interior of the  $\beta$ -barrel from bulk solvent. D, The aggregating G40 variant loses multiple van der Wäals interactions relative to its E40 counterpart. E, The aggregating D40 variant preserves charge, but introduces steric clashes (red discs, arrow) with residues in the 5-6 loop (see additional D40 rotamers/clashes in Figure S1). F, The short, branched side chain of the aggregating V40 variant also makes unfavorable contacts (red discs, arrow) with residues of the 5-6 loop (see text).

diminish strength of interaction between the two loop domains (Figure 3D). Mutation of E40 to D is predicted to weaken van der Wäals contacts or introduce a clash, depending on the rotamer examined (Figure 3E, Figure S1), while mutation to V is predicted to introduce a steric clash (Figure 3F). Asp cannot adopt the same extended conformation as Glu (it is one carbon shorter and there is no rotamer that permits it). By contrast, Gln at position 40 is predicted to behave identically to Glu because its side chain is the same length and can access the same rotamer

conformations. In addition, unlike Asp or Glu, a Gln side chain at position 40 could form a hydrogen bond with the carbonyl oxygen or side chain nitrogen of K91. When E40 is mutated to Val, however, there is no way to avoid a steric clash with residues of the  $\beta$ -hairpin as all possible rotamers of V40 introduce steric clashes that would disrupt the surface complementarity between the  $\beta$ -hairpin and omega loop elements in this region (Figure 3F). In 23 protomers, K91 makes no hydrogen bond (see Figure 3A), suggesting that the loss of favorable

aliphatic interactions between the  $\beta$  and  $\gamma$  carbons of E40 with the backbone of the 93 loop and the  $\beta$  carbon of K91 is deleterious. Thus, we can explain the behavior of the mutations made at E40 based on preservation or abolition of structure-stabilizing van der Wäals interactions between residues E40 and K91, located in two juxtaposed  $\beta$ -hairpins structures.

To analyze how mutations in the Zn loop may produce aggregation, position E133 was mutated to ALS mutants E133V or an in-frame deletion (E133del), and experimental substitutions to Gly, Leu, Met, or to Asp (all as fusions of SOD1 with YFP). As expected for mutations associated with fALS, the E133V, and E133del variants produced inclusions at relatively high frequency (Table 1, Figure S2). Cells expressing the experimental constructs, E133G-SOD1:YFP, E133L-SOD1:YFP, E133M-SOD1:YFP, and E133D-SOD1:YFP, did not develop inclusion-like structures by 24 or 48 hr (Table 1; Figure S3). We verified similar levels of expression for each of these variants by immunoblotting (see Figure S4). Collectively, these findings indicated that position E40 has relatively low tolerance for mutation, even a conservative Glu to Asp mutation, whereas the E133 positon was more tolerant of mutation.

The Glu at residue 133 is positioned within an alpha helical segment of the protein in the Zn loop (loop IV). The two disease causing mutations, E133del and E133V, both induced aggregation of SOD1, but other nonconservative mutations including E133G, E133M, and E133L did not. The alpha helical segment that contains E133 is stabilized by an extensive network of hydrogen bonds and extensive van der Wäals interactions (Figure 4A). The loss of a residue at position 133 would be devastating to the structure of the electrostatic loop (loop VII) because residues C-terminal to 133 would become out-of-register, misaligned for stabilizing hydrogen bonds and optimal van der Wäals packing. As with E40V, the E133V mutation is likely to be destabilizing because the short, branched nature of the Val chain is predicted to clash with the nearby side chains Asn 127 and Asn 135; the reciprocal bonds between



**Figure 4** Local structure of the short alpha-helix in loop VII and predicted effects of E133 substitutions. *A*, The branched portion of E133 extends into the solvent far enough that there are no steric clashes with residues T137, N131, and N139. The reciprocal hydrogen bonds between N131 and N139 are critical to maintain the conformation of loop VII. *B-D*, The short, branched side chain of the aggregating V133 variant clashes with atoms of T137, N131, and N139 (discs, boxed) and these unfavorable interactions are predicted to disrupt the hydrogen bonds between N131 and N139. *E and F*, The extra methylene spacer in the non-aggregating V133 variants relative to the aggregating V133 variant relieves unfavorable steric clashes.

which are integral to the stabilization of the conformation of the electrostatic loop (Figure 4B-D). Substitution of E133 for Leu or Met is tolerated, probably because the extra methylene spacer in its side chain relative to Val eliminates steric clash of the branched portion of their side chains with Asn 127 and 135 (Figure 4E and F). Although normally destabilizing, substitution of E133 for Gly is tolerated, likely because it possesses no side chain with which to clash and the flexibility introduced by the Gly is offset by the preserved and extensive H-bonding network of the electrostatic loop and helix dipole capping by the zinc ion. Together, these data show an association between mutations at E133 that produce aggregation and the effects of the specific substitution on critical van der Wäals interactions and, or, hydrogen bond networks.

#### CONCLUSIONS

In the present study, we investigated how mutations in SOD1 that cause the protein to aggregate may destabilize native structure. SOD1 is a highly conserved protein and disease mutations are often found in positions that are highly conserved (Wang *et al.* 2006), begging the question of whether any amino acid substitution at these positions could cause the protein to aggregate. Similar to the disease-associated mutation E40G (ALS), mutations E40D and E40V induced aggregation. Disease-causing mutations at Glu 133, in-frame deletion or mutation to V, induced aggregation as expected; whereas three nonconservative mutations (G, L, and M) were as well-tolerated as was a conservative E133D mutation. Analysis of the local structure around positions 40 and 133 suggested that mutations that are predicted to disturb van der Wäals contacts or produce steric strain are associated with a higher propensity to aggregate (Table 1).

A study of a set of ALS mutations that are predicted to have minimal effects on structural stability also suggested that relatively subtle changes in structure can cause disease (Byström et al. 2010). Missense substitutions at surface residues D76, N86, D90, D101, and N139 have been identified in ALS patients. A subset of the known substitutions at these residues, such as D76V, N86K, D90V, were predicted to introduce steric strain; whereas as others, such as D76Y, N86D, N86S, and D101N were predicted to diminish critical hydrogen bonds or salt bridges between residues in different elements of the protein (Byström et al. 2010). Two ALS mutations in D101 are particularly interesting as D101G was predicted to eliminate van der Wäals interactions whereas D101N was predicted to be sterically neutral and affect only electrostatic interactions (Byström et al. 2010). In a prior study that compared the aggregation propensity of D101G and D101N, we observed that D101G variant showed a more rapid rate of aggregation in cultured cell models (Ayers et al. 2014a). In the data we present here, we find that the E40G mutation, which is also predicted to eliminate critical van der Wäals interactions while also introducing flexibility in the peptide backbone was highly prone to form inclusions (see Table 1). Interestingly, to our knowledge the E40G mutation has been found only in one patient that was described as having a slowly progressing disease (Bertolin et al. 2014); whereas the D101G and D101N mutations are associated with rapidly progressing disease (Prudencio et al. 2009).

Although the nature of the toxic form of mutant SOD1 in fALS remains imprecisely defined, it is clear that one consequence of diseasecausing mutations in SOD1 is to destabilize normal structure in a manner that facilitates aberrant homotypic self-assembly into higher order structures (Wang *et al.* 2009; Ivanova *et al.* 2014). Some pathogenic SOD1 variants, such as substitutions in the metal-binding loop elements [*e.g.* H80R, D124V (Seetharaman *et al.* 2009) and S134N (Elam *et al.* 2003)] cause reduced metal-binding (and as a consequence, reduced S-S oxidation) to promote monomerization (Arnesano *et al.*  2004; Doucette et al. 2004; Lindberg et al. 2004). For other variants, such as those studied here and by Byström et al. (2010), the impact of the specific substitution on protein structure appears to be more subtle and in some cases the effect is limited to disruption of local van der Wäals interactions or hydrogen bonds. Additionally, it has been suggested that mutations could induce structural changes that promote oligomerization in prelude to adopting more misfolded conformations and aggregation (Healy 2015). Evidence of oligomerized mutant SOD1 dimers has been observed in X-ray crystallography (Elam et al. 2003). A key observation in assessing these divergent potential mechanisms of mutant SOD1 aggregation is that regardless of the location of the mutation, the protein that appears to comprise such aggregates lack critical post-translational modifications, including incorporation of Cu and formation of intramolecular disulfide bonds (Jonsson et al. 2006a; Karch et al. 2009; Lelie et al. 2011). Given the importance of posttranslational modification in the stability of SOD1, there could be examples of mutations that have little impact on SOD1 structurally and instead alter some key interactions with the copper chaperone for SOD1, leaving the protein deficient in Cu, less mature, and vulnerable to misfolding (Winkler et al. 2010).

In a prior study of 11 different ALS mutations, Bruns *et al.* found that mutant SOD1 exhibited delayed folding kinetics without necessarily abrogating folding into conformations closely resembling WT SOD1 (Bruns and Kopito 2007). Recently, we observed that newly made ALS-mutant SOD1 was rapidly captured into growing cytoplasmic inclusions (Ayers *et al.* 2017). Immature SOD1, lacking an intramolecular disulfide bond, shows greater structural disorder than mature protein with an intact disulfide bond (Furukawa *et al.* 2016). In the context of these observations, the seeming subtle effects of aggregation-inducing substitutions in SOD1 on local folding could be amplified early in maturation of the protein to favor off-pathway folding into aggregation prone conformations.

Recently, Ivanova and colleagues identified several short segments of SOD1 sequence possessing a high propensity to form amyloid fibrils (Ivanova *et al.* 2014). These segments are solvent inaccessible in the mature, homodimeric form of the enzyme. Two of the segments, <sup>14</sup>VQGIINFE<sup>21</sup> and <sup>30</sup>KVWGSIKGL<sup>38</sup>, are involved in alignment of the  $\beta$ -barrel plug residue L38 and the apolar residues with which it interacts (V14, I18, I35, Figure 5). Nascent SOD1 proteins harboring destabilizing pathogenic substitutions in the  $\beta$ -barrel plug region (*e.g.* positions 38, 40, 93, and in the surrounding region; see Figure 5) are significantly destabilized relative to their wild type counterparts (Rodriguez *et al.* 2005), suggesting these segments may be more



**Figure 5** View of the local structure in the  $\beta$ -barrel plug of SOD1. Leu 38 forms the "plug" that seals the  $\beta$ -barrel structure. fALS mutations occur at multiple residues near L38, including L38 itself, G37, G93, G41, and V97 {http://alsod.iop.kcl.ac.uk}.

solvent-exposed and amenable to self-assembly in these variants. A third segment, <sup>147</sup>GVIGIAQ<sup>153</sup>, is buried at the homodimer interface in the mature enzyme, but exposed to bulk solvent in newly translated, monomeric forms (Seetharaman *et al.* 2009). Our findings fit with a model in which aggregation-causing substitutions at positions 40 and 133 introduce steric clashes and, or, destabilize van der Wäals interactions; thereby slowing maturation of the protein and increasing the probability of aberrant self-assembly mediated by inherently amyloidogenic sequences in SOD1.

#### **ACKNOWLEDGMENTS**

We are grateful for helpful advice from Drs. Julian Whitelegge, David Eisenberg, and Joan S. Valentine. We thank undergraduate students Aron Workman, Adam DeBossier, and Kinaree Patel for their contributions to this study. This work was supported by a grant from the National Institutes of Neurological Disorders and Stroke (P01 NS049134), by a Merit Review Award from the U.S. Department of Veteran's Affairs, # I01 BX00056 (PJH) and by the Robert A. Welch Foundation grant AQ-1399 (PJH). Disclaimer: The contents do not represent the views of the U.S. Department of Veteran's Affairs or the United States Government.

#### LITERATURE CITED

- Abdolvahabi, A., Y. Shi, A. Chuprin, S. Rasouli, and B. F. Shaw, 2016 Stochastic Formation of Fibrillar and Amorphous Superoxide Dismutase Oligomers Linked to Amyotrophic Lateral Sclerosis. ACS Chem. Neurosci. 7: 799–810. https://doi.org/10.1021/acschemneuro.6b00048
- Abdolvahabi, A., Y. Shi, N. R. Rhodes, N. P. Cook, A. A. Marti *et al.*, 2015 Arresting amyloid with coulomb's law: acetylation of ALS-linked SOD1 by aspirin impedes aggregation. Biophys. J. 108: 1199–1212. https://doi.org/10.1016/j.bpj.2015.01.014
- Arnesano, F., L. Banci, I. Bertini, M. Martinelli, Y. Furukawa *et al.*, 2004 The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J. Biol. Chem. 279: 47998–48003. https://doi.org/10.1074/jbc.M406021200
- Ayers, J., H. Lelie, A. Workman, M. Prudencio, H. Brown et al., 2014a Distinctive features of the D101N and D101G variants of superoxide dismutase 1; Two mutations that produce rapidly progressing motor neuron disease. J. Neurochem. 128: 305–314. https://doi.org/ 10.1111/jnc.12451
- Ayers, J. I., B. McMahon, S. Gill, H. L. Lelie, S. Fromholt *et al.*, 2017 Relationship between mutant Cu/Zn superoxide dismutase 1 maturation and inclusion formation in cell models. J. Neurochem. 140: 140–150. https://doi.org/10.1111/jnc.13864
- Ayers, J. I., G. Xu, O. Pletnikova, J. C. C. Troncoso, P. J. J. Hart *et al.*, 2014b Conformatonal specificity of the C4F6 SOD1 antibody; low frequency of reactivity in sporadic ALS cases. Acta Neuropathol. Commun. 2: 55. https://doi.org/10.1186/2051-5960-2-55
- Banci, L., I. Bertini, M. Boca, S. Girotto, M. Martinelli *et al.*, 2008 SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization. PLoS One 3: e1677. https://doi.org/10.1371/journal.pone.0001677
- Bertolin, C., C. D'Ascenzo, G. Querin, A. Gaiani, F. Boaretto *et al.*, 2014 Improving the knowledge of amyotrophic lateral sclerosis genetics: novel SOD1 and FUS variants. Neurobiol. Aging 35: 1212.e7–1212. e10. https://doi.org/10.1016/j.neurobiolaging.2013.10.093
- Borchelt, D. R. R., M. K. K. Lee, H. S. S. Slunt, M. Guarnieri, Z.-S. S. Xu et al., 1994 Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. USA 91: 8292–8296. https://doi.org/10.1073/pnas.91.17.8292
- Bosco, D. A., G. Morfini, N. M. Karabacak, Y. Song, F. Gros-Louis *et al.*, 2010 Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 13: 1396–1403. https://doi.org/10.1038/nn.2660

- Brotherton, T. E., Y. Li, D. Cooper, M. Gearing, J. P. Julien *et al.*, 2012 Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc. Natl. Acad. Sci. USA 109: 5505–5510. https://doi.org/10.1073/pnas.1115009109
- Bruns, C. K., and R. R. Kopito, 2007 Impaired post-translational folding of familial ALS-linked Cu, Zn superoxide dismutase mutants. EMBO J. 26: 855–866. https://doi.org/10.1038/sj.emboj.7601528
- Byström, R., P. M. Andersen, G. Gröbner, and M. Oliveberg, 2010 SOD1 mutations targeting surface hydrogen bonds promote amyotrophic lateral sclerosis without reducing apo-state stability. J. Biol. Chem. 285: 19544–19552. https://doi.org/10.1074/jbc.M109.086074
- Chattopadhyay, M., A. Durazo, S. H. Sohn, C. D. Strong, E. B. Gralla et al., 2008 Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc. Natl. Acad. Sci. USA 105: 18663–18668. https://doi.org/ 10.1073/pnas.0807058105
- Chattopadhyay, M., E. Nwadibia, C. D. Strong, E. B. Gralla, J. S. Valentine et al., 2015 The Disulfide Bond, but Not Zinc or Dimerization, Controls Initiation and Seeded Growth in Amyotrophic Lateral Sclerosis-linked Cu,Zn Superoxide Dismutase (SOD1). Fibrillation. J. Biol. Chem. 290: 30624–30636. https://doi.org/10.1074/jbc.M115.666503
- Choi, I., Y. I. Yang, H. D. Song, J. S. Lee, T. Kang et al., 2011 Lipid molecules induce the cytotoxic aggregation of Cu/Zn superoxide dismutase with structurally disordered regions. Biochim. Biophys. Acta 1812: 41–48. https://doi.org/10.1016/j.bbadis.2010.09.003
- Corcoran, L. J., T. J. Mitchison, and Q. Liu, 2004 A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr. Biol. 14: 488–492. https://doi.org/10.1016/j.cub.2004.03.003
- Da Cruz, S., A. Bui, S. Saberi, S. K. Lee, J. Stauffer *et al.*, 2017 Misfolded SOD1 is not a primary component of sporadic ALS. Acta Neuropathol. 134: 97–111. https://doi.org/10.1007/s00401-017-1688-8
- DiDonato, M., L. Craig, M. E. Huff, M. M. Thayer, R. M. Cardoso et al., 2003 ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J. Mol. Biol. 332: 601–615. https:// doi.org/10.1016/S0022-2836(03)00889-1
- Doucette, P. A., L. J. Whitson, X. Cao, V. Schirf, B. Demeler *et al.*, 2004 Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant. Insights into the molecular basis for dimer stability. J. Biol. Chem. 279: 54558–54566. https://doi.org/10.1074/ jbc.M409744200
- Elam, J. S., A. B. Taylor, R. Strange, S. Antonyuk, P. A. Doucette *et al.*, 2003 Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat. Struct. Biol. 10: 461–467. https://doi.org/10.1038/nsb935
- Fei, E., N. Jia, M. Yan, Z. Ying, Q. Sun *et al.*, 2006 SUMO-1 modification increases human SOD1 stability and aggregation. Biochem. Biophys. Res. Commun. 347: 406–412. https://doi.org/10.1016/j.bbrc.2006.06.092
- Forsberg, K., P. A. Jonsson, P. M. Andersen, D. Bergemalm, K. S. Graffmo et al., 2010 Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 5: e11552. https://doi.org/ 10.1371/journal.pone.0011552
- Fridovich, I., 1974 Superoxide dismutases. Adv. Enzymol. Relat. Areas Mol. Biol. 41: 35–97.
- Furukawa, Y., I. Anzai, S. Akiyama, M. Imai, F. J. Cruz *et al.*,
  2016 Conformational Disorder of the Most Immature Cu,
  Zn-Superoxide Dismutase Leading to Amyotrophic Lateral Sclerosis.
  J. Biol. Chem. 291: 4144–4155. https://doi.org/10.1074/jbc.M115.683763
- Furukawa, Y., K. Kaneko, K. Yamanaka, and N. Nukina, 2010 Mutationdependent polymorphism of Cu,Zn-superoxide dismutase aggregates in the familial form of amyotrophic lateral sclerosis. J. Biol. Chem. 285: 22221–22231. https://doi.org/10.1074/jbc.M110.113597
- Furukawa, Y., and T. V. O'Halloran, 2005 Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. J. Biol. Chem. 280: 17266–17274. https://doi.org/10.1074/jbc.M500482200
- Grad, L. I., J. J. Yerbury, B. J. Turner, W. C. Guest, E. Pokrishevsky et al., 2014 Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent

mechanisms. Proc. Natl. Acad. Sci. USA 111: 3620–3625. https://doi.org/ 10.1073/pnas.1312245111

Graffmo, K. S., K. Forsberg, J. Bergh, A. Birve, P. Zetterstrom *et al.*, 2013 Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum. Mol. Genet. 22: 51–60. https:// doi.org/10.1093/hmg/dds399

Gurney, M. E., H. Pu, A. Y. Chiu, M. C. D. Canto, C. Y. Polchow *et al.*, 1994 Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772–1775. https://doi.org/ 10.1126/science.8209258

Hart, P. J., M. M. Balbirnie, N. L. Ogihara, A. M. Nersissian, M. S. Weiss et al., 1999 A structure-based mechanism for copper-zinc superoxide dismutase. Biochemistry 38: 2167–2178. https://doi.org/10.1021/ bi982284u

Hart, P. J., H. Liu, M. Pellegrini, A. M. Nersissian, E. B. Gralla *et al.*, 1998 Subunit asymmetry in the three-dimensional structure of a human CuZnSOD mutant found in familial amyotrophic lateral sclerosis. Protein Sci. 7: 545–555. https://doi.org/10.1002/pro.5560070302

Hayward, L. J., J. A. Rodriguez, J. W. Kim, A. Tiwari, J. J. Goto *et al.*,
2002 Decreased Metallation and Activity in Subsets of Mutant Superoxide Dismutases Associated with Familial Amyotrophic Lateral Sclerosis. J. Biol. Chem. 277: 15923–15931. https://doi.org/10.1074/jbc.M112087200

Healy, E. F., 2015 A model for non-obligate oligomer formation in protein aggregration. Biochem. Biophys. Res. Commun. 465: 523–527. https://doi. org/10.1016/j.bbrc.2015.08.052

Hineno, A., A. Nakamura, Y. Shimojima, K. Yoshida, K. Oyanagai *et al.*,
2012 Distinctive clinicopathological features of 2 large families with amyotrophic lateral sclerosis having L106V mutation in SOD1 gene.
J. Neurol. Sci. 319: 63–74. https://doi.org/10.1016/j.jns.2012.05.014

Hwang, Y. M., P. B. Stathopulos, K. Dimmick, H. Yang, H. R. Badiei *et al.*, 2010 Nonamyloid aggregates arising from mature copper/zinc superoxide dismutases resemble those observed in amyotrophic lateral sclerosis. J. Biol. Chem. 285: 41701–41711. https://doi.org/10.1074/jbc. M110.113696

Ivanova, M. I., S. A. Sievers, E. L. Guenther, L. M. Johnson, D. D. Winkler et al., 2014 Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. Proc. Natl. Acad. Sci. USA 111: 197–201. https://doi.org/10.1073/pnas.1320786110

Johnston, J. A., M. J. Dalton, M. E. Gurney, and R. R. Kopito, 2000 Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 97: 12571–12576. https:// doi.org/10.1073/pnas.220417997

Jonsson, P. A., D. Bergemalm, P. M. Andersen, O. Gredal, T. Brannstrom et al., 2008 Inclusions of amyotrophic lateral sclerosis-linked superoxide dismutase in ventral horns, liver, and kidney. Ann. Neurol. 63: 671–675. https://doi.org/10.1002/ana.21356

Jonsson, P. A., K. Ernhill, P. M. Andersen, D. Bergemalm, T. Brannstrom et al., 2004 Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain 127: 73–88. https://doi. org/10.1093/brain/awh005

Jonsson, P. A., K. S. Graffmo, P. M. Andersen, T. Brannstrom, M. Lindberg et al., 2006a Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 129: 451–464. https://doi.org/10.1093/brain/awh704

Jonsson, P. A., K. S. Graffmo, T. Brannstrom, P. Nilsson, P. M. Andersen et al., 2006b Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1. J. Neuropathol. Exp. Neurol. 65: 1126–1136. https://doi.org/10.1097/01.jnen.0000248545.36046.3c

Karch, C. M., and D. R. Borchelt, 2008 A limited role for disulfide crosslinking in the aggregation of mutant SOD1 linked to familial amyotrophic lateral sclerosis. J. Biol. Chem. 283: 13528–13537. https://doi.org/10.1074/ jbc.M800564200

Karch, C. M. M., M. Prudencio, D. D. D. Winkler, P. J. J. Hart, and D. R. R. Borchelt, 2009 Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc. Natl. Acad. Sci. USA 106: 7774–7779. https://doi.org/10.1073/pnas.0902505106 Kato, S., H. Sumi-Akamaru, H. Fujimura, S. Sakoda, M. Kato *et al.*, 2001 Copper chaperone for superoxide dismutase co-aggregates with superoxide dismutase 1 (SOD1) in neuronal Lewy body-like hyaline inclusions: an immunohistochemical study on familial amyotrophic lateral sclerosis with SOD1 gene mutation. Acta Neuropathol. 102: 233–238.

Kerman, A., H. N. Liu, S. Croul, J. Bilbao, E. Rogaeva *et al.*, 2010 Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 119: 335–344. https://doi.org/10.1007/s00401-010-0646-5

Kokubo, Y., S. Kuzuhara, Y. Narita, K. Kikugawa, R. Nakano et al., 1999 Accumulation of neurofilaments and SOD1-immunoreactive products in a patient with familial amyotrophic lateral sclerosis with 1113T SOD1 mutation. Arch. Neurol. 56: 1506–1508. https://doi.org/ 10.1001/archneur.56.12.1506

Lelie, H. L., A. Liba, M. W. Bourassa, M. Chattopadhyay, P. K. Chan *et al.*, 2011 Copper and zinc metallation status of copper-zinc superoxide dismutase from amyotrophic lateral sclerosis transgenic mice. J. Biol. Chem. 286: 2795–2806. https://doi.org/10.1074/jbc.M110.186999

Lindberg, M. J., J. Normark, A. Holmgren, and M. Oliveberg, 2004 Folding of human superoxide dismutase: disulfide reduction prevents dimerization and produces marginally stable monomers. Proc. Natl. Acad. Sci. USA 101: 15893–15898. https://doi.org/10.1073/pnas.0403979101

Matsumoto, G., A. Stojanovic, C. I. Holmberg, S. Kim, and R. I. Morimoto, 2005 Structural properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. J. Cell Biol. 171: 75–85. https://doi.org/10.1083/jcb.200504050

McCord, J. M., and I. Fridovich, 1969 Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244: 6049–6055.

Mizushima, S., and S. Nagata, 1990 pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18: 5322. https://doi.org/10.1093/nar/ 18.17.5322

Münch, C., and A. Bertolotti, 2010 Exposure of hydrophobic surfaces initiates aggregation of diverse ALS-causing superoxide dismutase-1 mutants. J. Mol. Biol. 399: 512–525. https://doi.org/10.1016/j. imb.2010.04.019

Nakamura, S., R. Wate, S. Kaneko, H. Ito, M. Oki et al., 2014 An autopsy case of sporadic amyotrophic lateral sclerosis associated with the II13T SOD1 mutation. Neuropathology 34: 58–63. https://doi.org/10.1111/ neup.12049

Nishida, C. R., E. B. Gralla, and J. S. Valentine, 1994 Characterization of three yeast copper-zinc superoxide dismutase mutants analogous to those coded for in familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 91: 9906–9910. https://doi.org/10.1073/pnas.91.21.9906

Ogihara, N. L., H. E. Parge, P. J. Hart, M. S. Weiss, J. J. Goto *et al.*, 1996 Unusual trigonal-planar copper configuration revealed in the atomic structure of yeast copper-zinc superoxide dismutase. Biochemistry 35: 2316–2321. https://doi.org/10.1021/bi951930b

Ohi, T., K. Nabeshima, S. Kato, S. Yazawa, and S. Takechi, 2004 Familial amyotrophic lateral sclerosis with His46Arg mutation in Cu/Zn superoxide dismutase presenting characteristic clinical features and Lewy body-like hyaline inclusions. J. Neurol. Sci. 225: 19–25. https://doi.org/ 10.1016/j.jns.2004.06.008

Parge, H. E., R. A. Hallewell, and J. A. Tainer, 1992 Atomic structures of wild-type and thermostable mutant recombinant human Cu,Zn superoxide dismutase. Proc. Natl. Acad. Sci. USA 89: 6109–6113. https:// doi.org/10.1073/pnas.89.13.6109

Pratt, A. J., D. S. Shin, G. E. Merz, R. P. Rambo, W. A. Lancaster *et al.*, 2014 Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes. Proc. Natl. Acad. Sci. USA 111: E4568–E4576. https://doi.org/10.1073/pnas.1308531111

Prudencio, M., and D. R. Borchelt, 2011 Superoxide dismutase 1 encoding mutations linked to ALS adopts a spectrum of misfolded states. Mol. Neurodegener. 6: 77. https://doi.org/10.1186/1750-1326-6-77

Prudencio, M., P. J. J. Hart, D. R. R. Borchelt, and P. M. M. Andersen, 2009 Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum. Mol. Genet. 18: 3217–3226. https://doi.org/10.1093/hmg/ddp260 Rakhit, R., P. Cunningham, A. Furtos-Matei, S. Dahan, X. F. Qi et al., 2002 Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 277: 47551–47556. https://doi.org/10.1074/jbc.M207356200

Ratovitski, T., L. B. Corson, J. Strain, P. Wong, D. W. Cleveland *et al.*, 1999 Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum. Mol. Genet. 8: 1451–1460.

Roberts, B. L. T. L., K. Patel, H. H. H. Brown, and D. R. R. Borchelt, 2012 Role of disulfide cross-linking of mutant SOD1 in the formation of inclusion-body-like structures. PLoS One 7: e47838. https://doi.org/ 10.1371/journal.pone.0047838

Rodriguez, J. A., B. F. Shaw, A. Durazo, S. H. Sohn, P. A. Doucette *et al.*, 2005 Destabilization of apoprotein is insufficient to explain Cu,Zn-superoxide dismutase-linked ALS pathogenesis. Proc. Natl. Acad. Sci. USA 102: 10516–10521. https://doi.org/10.1073/pnas.0502515102

Rosen, D. R., T. Siddique, D. Patterson, D. A. Figlewicz, P. Sapp *et al.*, 1993 Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62. Erratum: 364:362. https://doi.org/10.1038/362059a0

Sábado, J., A. Casanovas, S. Hernandez, L. Piedrafita, M. Hereu et al., 2013 Immunodetection of disease-associated conformers of mutant cu/ zn superoxide dismutase 1 selectively expressed in degenerating neurons in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 72: 646–661. https://doi.org/10.1097/NEN.0b013e318297fd10

Sasaki, S., Y. Ohsawa, K. Yamane, H. Sakuma, N. Shibata *et al.*,
1998 Familial amyotrophic lateral sclerosis with widespread vacuolation and hyaline inclusions. Neurology 51: 871–873. https://doi.org/10.1212/ WNL.51.3.871

Seetharaman, S. V. V., M. Prudencio, C. Karch, S. P. P. Holloway,
D. R. R. Borchelt *et al.*, 2009 Immature Copper-zinc Superoxide Dismutase and Familial Amyotrophic Lateral Sclerosis. Exp. Biol. Med. (Maywood) 234: 1140–1154. https://doi.org/10.3181/0903-MR-104

Shaw, C. E., Z. E. Enayat, J. F. Powell, V. E. Anderson, A. Radunovic et al., 1997 Familial amyotrophic lateral sclerosis. Molecular pathology of a patient with a SOD1 mutation. Neurology 49: 1612–1616. https://doi.org/ 10.1212/WNL49.6.1612

Shibata, N., K. Asayama, A. Hirano, and M. Kobayashi, 1996a Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Dev. Neurosci. 18: 492–498. https://doi.org/10.1159/000111445

Shibata, N., A. Hirano, M. Kobayashi, T. Siddique, H. X. Deng et al., 1996b Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J. Neuropathol. Exp. Neurol. 55: 481–490. https://doi.org/10.1097/00005072-199604000-00011

Shinder, G. A., M. C. Lacourse, S. Minotti, and H. D. Durham, 2001 Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol. Chem. 276: 12791–12796. https://doi.org/10.1074/jbc.M010759200

Steinacker, P., C. Berner, D. R. Thal, J. Attems, A. C. Ludolph *et al.*, 2014 Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot. Acta Neuropathol. Commun. 2: 130–014–0130–x.

Strange, R. W., C. W. Yong, W. Smith, and S. S. Hasnain, 2007 Molecular dynamics using atomic-resolution structure reveal structural fluctuations that may lead to polymerization of human Cu-Zn superoxide dismutase. Proc. Natl. Acad. Sci. USA 104: 10040–10044. https://doi.org/10.1073/ pnas.0703857104

Suzuki, M., T. Irie, T. Watanabe, H. Mikami, T. Yamazaki *et al.*,
2008 Familial amyotrophic lateral sclerosis with Gly93Ser mutation in Cu/Zn superoxide dismutase: a clinical and neuropathological study.
J. Neurol. Sci. 268: 140–144. https://doi.org/10.1016/j.jns.2007.11.020 Takehisa, Y., H. Ujike, H. Ishizu, S. Terada, T. Haraguchi *et al.*, 2001 Familial amyotrophic lateral sclerosis with a novel Leu126Ser mutation in the copper/zinc superoxide dismutase gene showing mild clinical features and lewy body-like hyaline inclusions. Arch. Neurol. 58: 736–740. https://doi.org/10.1001/archneur.58.5.736

Tan, C. F., Y. S. Piao, S. Hayashi, H. Obata, Y. Umeda *et al.*, 2004 Familial amyotrophic lateral sclerosis with bulbar onset and a novel Asp101Tyr Cu/Zn superoxide dismutase gene mutation. Acta Neuropathol. 108: 332–336. https://doi.org/10.1007/s00401-004-0893-4

Turner, B. J., J. D. Atkin, M. A. Farg, D. W. Zang, A. Rembach *et al.*,
2005 Impaired extracellular secretion of mutant superoxide dismutase
1 associates with neurotoxicity in familial amyotrophic lateral sclerosis.
J. Neurosci. 25: 108–117. https://doi.org/10.1523/JNEUROSCI.4253-04.2005

Urushitani, M., S. A. Ezzi, A. Matsuo, I. Tooyama, and J. P. Julien, 2008 The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase linked to ALS. FASEB J. 22: 2476–2487. https://doi.org/10.1096/fj.07-092783

Vassall, K. A., H. R. Stubbs, H. A. Primmer, M. S. Tong, S. M. Sullivan et al., 2011 Decreased stability and increased formation of soluble aggregates by immature superoxide dismutase do not account for disease severity in ALS. Proc. Natl. Acad. Sci. USA 108: 2210–2215. https://doi.org/10.1073/pnas.0913021108

Wang, J., G. W. Farr, C. J. Zeiss, D. J. Rodriguez-Gil, J. H. Wilson *et al.*, 2009 Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc. Natl. Acad. Sci. USA 106: 1392–1397. https://doi.org/10.1073/pnas.0813045106

Wang, J., H. Slunt, V. Gonzales, D. Fromholt, M. Coonfield *et al.*,
2003 Copper-binding-site-null SOD1 causes ALS in transgenic mice:
Aggregates of non-native SOD1 delineate a common feature. Hum. Mol. Genet. 12: 2753–1264.

Wang, J., G. Xu, and D. R. Borchelt, 2002 High molecular weight complexes of mutant superoxide dismutase 1: age- dependent and tissue-specific accumulation. Neurobiol. Dis. 9: 139–148. https://doi.org/10.1006/nbdi.2001.0471

Wang, J., G. Xu, and D. R. Borchelt, 2006 Mapping superoxide dismutase 1 domains of non-native interaction: Roles of intra- and intermolecular disulfide bonding in aggregation. J. Neurochem. 96: 1277–1288.

Wang, J., G. Xu, H. Li, V. Gonzales, D. Fromholt *et al.*, 2005 Somatodendritic accumulation of misfolded SOD1–L126Z in motor neurons mediates degeneration: αB-crystallin modulates aggregation. Hum. Mol. Genet. 14: 2335–1247.

Wiedau-Pazos, M., J. J. Goto, S. Rabizadeh, E. B. Gralla, J. A. Roe et al., 1996 Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271: 515–518. https://doi.org/10.1126/ science.271.5248.515

Winkler, D. D., M. Prudencio, C. Karch, D. R. Borchelt, and P. J. Hart, 2010 Copper-Zinc Superoxide Dismutase, Its Copper Chaperone, and Familial Amyotrophic Lateral Sclerosis, edited by Ramirez-Alvarado, M., J. W. Kelly, and C. M. Dobson. John Wiley & Sons, Hoboken, NJ. https:// doi.org/10.1002/9780470572702.ch17

Witan, H., P. Gorlovoy, A. M. Kaya, I. Koziollek-Drechsler, H. Neumann et al., 2009 Wild-type Cu/Zn superoxide dismutase (SOD1) does not facilitate, but impedes the formation of protein aggregates of amyotrophic lateral sclerosis causing mutant SOD1. Neurobiol. Dis. 36: 331–342. https://doi.org/10.1016/j.nbd.2009.07.024

Wong, P. C., C. A. Pardo, D. R. Borchelt, M. K. Lee, N. G. Copeland *et al.*, 1995 An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105–1116. https://doi.org/10.1016/0896-6273(95)90259-7

Zhang, F., and H. Zhu, 2006 Intracellular conformational alterations of mutant SOD1 and the implications for fALS-associated SOD1 mutant induced motor neuron cell death. Biochim. Biophys. Acta 1760: 404–414. https://doi.org/10.1016/j.bbagen.2005.11.024

Communicating Editor: B. Andrews